MAPT and Alzheimer disease: The most common pharmacological interventions for AD are natural products (25.6%), anti-Aβ compounds (13.3%), neurotransmitter enhancers (11.4%), multi-target- (2.5%) and anti-tau drugs (2.3%) [10].